The GLP-1 receptor in airway inflammation in asthma: a promising novel target?

Figures & data

Table 1. Current FDA-approved GLP-1R agonists and dosing

GLP-1R Agonist	Route	Dosing
Short-acting
Exenatide	SC	Twice daily
Lixisenatide	SC	Once daily
Long-acting
Exenatide extended release	SC	Once weekly
Liraglutide^a	SC	Once daily
Dulaglutide	SC	Once weekly
Semaglutide^a	SC or PO	Once weekly SC or once daily PO

^aAll GLP-1R agonists are currently approved for use in T2D with the exception of liraglutide and semaglutide, which are also approved for chronic weight management and weight loss in obesity

GLP-1R, glucagon-like peptide-1 receptor; T2D, type 2 diabetes mellitus; SC, subcutaneous; PO, oral.

Figure 1. Various mechanisms have been proposed for the role of GLP-1R agonists in reducing inflammatory airway disease, including airway modification with increased surfactant production and decreased mucus secretion, decreased Type 2 inflammatory signaling, and increased smooth muscle relaxation